Clinical trials: Immunochemotherapy
Burkitt's Lymphoma, High-grade B-cell Lymphoma
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features…
- Trial name
- RBL (NCT01809600)
- Testing
- No intervention (observational study)
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Gachon University Gil Medical Center
Neoplasms, Carcinoma, Squamous
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Nivolumab + carboplatin + paclitaxel in 25 newly diagnosed patients with primary tracheal squamous cell carcinoma.
- Conditions
- Neoplasms, Carcinoma, Squamous, Antineoplastic Agents
- Trial name
- GALAXY-1 (NCT05964101)
- Testing
- Nivolumab Injection [Opdivo]
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
This study aims to investigate the clinical value of small extracellular vesicle (sEV) miRNAs as predictive biomarkers for immunochemotherapy efficacy in extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- NCT07070011
- Testing
- EC/EP + ICIs
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Chest Hospital of Shanghai Jiao Tong University
Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer
This is a single-arm interventional study targeting patients with initially unresectable MSS-type advanced colorectal cancer with liver and/or lung and peritoneal metastasis.
- Trial name
- NCT07512674
- Testing
- Receiving lymph node-sparing modified short-course radiotherapy combined with tislelizumab, CAPOX chemotherapy and bevacizumab targeted therapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Posttransplant Lymphoproliferative Disorder
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
Post-transplant lymphoproliferative disorders (PTLD) differ clinically from lymphoma in the general (immunocompetent) population due to their higher incidence and their frequent association with Epstein-Barr virus.
- Trial name
- PTLD-2 (NCT02042391)
- Testing
- Rituximab sc, Rituximab sc consolidation, Rituximab sc combined with CHOP chemotherapy
- Where
- 18 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH
Non-small Cell Lung Cancer
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.
- Trial name
- LungTIME-C01 (NCT05549037)
- Testing
- Pembrolizumab, Sintilimab
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Hunan Province Tumor Hospital
Esophageal Squamous Cell Carcinoma
Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
This study is a prospective, multicenter, open-label, observational cohort study. The primary endpoint is pathological complete response (pCR), and the secondary endpoints include R0 resection rate, ctDNA clearance rate, major…
- Trial name
- ctDNA (NCT06103890)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Medical University Fourth Hospital
Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
SCR-ESCC-02 is a multicenter, phase I/II clinical study to investigate the safety and efficacy of induction immunochemotherapy followed by concurrent chemoradiotherapy with anti-PD-1 therapy in patients diagnosed with locally…
- Trial name
- NCT06173986
- Testing
- PD-1inhibitor, nab-paclitaxel + cisplatin, Radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Triple-negative Breast Cancer (TNBC)
Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer
The goal of this clinical trial is to identify cellular and molecular determinants of response to neoadjuvant immunochemotherapy in women aged 18 or older with early-stage triple-negative breast cancer (TNBC).
- Trial name
- PRIME-TNBC (NCT07570524)
- Testing
- Additionnal breast biospy and blood sample
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Center Eugene Marquis
Non-small Cell Lung Cancer Stage III
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Patients with stage III non-small-cell lung cancer initially evaluated as unresectable are selected for the program, who are remained unresectable after 2-4 cycles of conversion chemotherapy combined with immune checkpoint…
- Trial name
- NCT06031597
- Testing
- radiotherapy, Platinum-Based Drug, Immunotherapy
- Volunteers
- 105 people
- Sponsor
- Zhejiang Cancer Hospital
Non-Small Cell Lung Cancer
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
This study will review medical records from hospitals in Poland to describe the demographics and baseline clinical characteristics of adults with advanced non-small cell lung cancer who received first-line nivolumab plus…
- Trial name
- NCT07526961
- Testing
- Nivolumab + Ipilimumab + Chemotherapy
- Where
- Poland
- Volunteers
- 240 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer (NSCLC)
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
The goal of this clinical trial is to evaluate the clinical value of ctDNA testing in guiding the optimization of immunochemotherapy cycles during induction treatment for resectable patients with NSCLC.
- Trial name
- PROPHET (NCT06977074)
- Testing
- PD-1 inhibitor, Platinum Doublet
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Sun Yat-sen University
BTK Inhibitors, Follicular Lymphoma
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
Previously untreated patients with follicular lymphoma are treated with the ZGCVP regimen (zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, prednisolone) for 6 cycles.
- Conditions
- BTK Inhibitors, Follicular Lymphoma, Immunochemotherapy
- Trial name
- NCT06918015
- Testing
- ZGCVP
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, Triple Negative Breast Cancer
Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment
In this randomized, controlled, prospective, two-arm intervention study, the investigators plan to investigate the effects of high-intensity interval training in women diagnosed with triple-negative breast cancer.
- Trial name
- NCT06497322
- Testing
- Exercise intervention - High intensity interval training on a cycle-ergometer
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital of Cologne
Relapsed or Refractory Multiple Myeloma
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.
- Trial name
- NCT01670994
- Testing
- ALT-801
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Altor BioScience
Diffuse Large B-cell Lymphoma
Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL
This study aims; to assess the efficacy of shortened systemic chemotherapy in patients with completely excised CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) with Ann Arbor Stage I or II.
- Trial name
- NCT01279902
- Testing
- Rituximab plus CHOP Immunochemotherapy
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Asan Medical Center
Cutaneous Leishmaniasis
Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
This study will test whether addition of imiquimod to standard antimony therapy provides a significant benefit in subjects with newly diagnosed cutaneous leishmaniasis.
- Trial name
- NCT00257530
- Testing
- Imiquimod
- Where
- 2 sites in Peru
- Volunteers
- 80 people
- Sponsor
- Drugs for Neglected Diseases
SCLC, Extensive Stage
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
This study hypothesizes that nanocrystalline megestrol acetate can improve the cachexia condition in patients and enhance the efficacy of immunochemotherapy regimens.
- Trial name
- NCT06793228
- Testing
- Nanocrystalline Megestrol Acetate, Tislelizumab, PTOC
- Where
- 4 sites in China
- Volunteers
- 250 people
- Sponsor
- Henan Cancer Hospital
Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant immunochemotherapy (NAIC) has demonstrated promising pathological and survival outcomes in patients with resectable locally advanced oral and oropharyngeal squamous cell carcinoma (LA-OSCC/OPSCC).
- Trial name
- NCT07457099
- Testing
- Observation, Postoperative Radiotherapy, PD-1 Inhibitor Maintenance Therapy
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Zhujiang Hospital
B-cell Chronic Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)
This study aims to assess the short term efficacy of a combination immunochemotherapy in patients with relapsed B-cell chronic lymphatic leukemia.
- Trial name
- NCT00147901
- Testing
- FCCam
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- German CLL Study Group